Morepen Laboratories , the Indian pharmaceutical company is preparing to expand its sales team by adding at least 1,000 medical representatives. While 200 new hires will join in FY26 itself, the rest will be added over a period of three years, that is, by 2028.
The objective is to “sharpen focus on the expanding domestic finished dosage market,” said Sushil Suri, chairman and managing director, Morepen Laboratories.
The endeavour is to “set the stage for getting a bigger pie in the Indian pharmaceutical market valued at ?2.38 lakhcrore, yielding higher gross margins and better returns for stakeholders in the long run,” added Suri.
Morepen is trying to build on its strong legacy as a leading exporter of active phramaceutical ingredient (API) for six leading products including Loratadine, Montelukast, Desloratadine, Atorvastatin, Rosuvastatin, and Fexofenadine. The company continues to reinforce investor confidence through consistent financial performance, global quality standards, and a forward-looking growth strategy.
While Morepen’s formulation business stands at about Rs 325 crore, the company is targeting a Rs 1,000 crore finished dosages business within the next five years.
This expansion effort will improve its medical representative network and ensure deeper market penetration across urban and rural India, with major growth expected from new products that the company is already producing at highly competitive costs.
The Indian pharmaceutical market is projected to reach $130 billion in 2030, with an expected annual growth rate of 8.2 per cent. Morepen’s strong presence and proven product portfolio, coupled with robust manufacturing capabilities, will enable it to better serve the evolving needs of Indian healthcare while continuing its double-digit growth trajectory.
